Condition: Neuroendocrine Tumors · Neuroendocrine Tumor Grade 1 · Neuroendocrine Tumor Grade 2 · Sponsor: University of Iowa
The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatment outcomes for adults with unresectable neuroendocrine tumors. To investigate this, study participants will: * Undergo Somatostatin Receptor (SSTR) positron emission tomography (PET) imaging, such as a DOTATOC PET/CT scan * Be randomized to receive standard treatment (as per FDA guidelines) or investigational treatment (customized dosing of Lutathera based upon dosimetry) * Undergo blood tests for 4 to 8 weeks after each Lutathera treatment * Complete patient reported outcome questionnaires * Visit the clinic for follow-up about every 8 weeks.
This description comes directly from the study's public registry record.
Stephen A Graves, Ph.D., DABR · +1 319 356 3656 · stephen-a-graves@uiowa.edu
Yusuf Menda, MD · +1 319 356 3656 · yusuf-menda@uiowa.edu
Always discuss trial participation with your own doctor first.
| Holden Comprehensive Cancer Center at the University of Iowa | Iowa City, Iowa, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06395402